No pharmaceutical company has pursued the TB-500 fragment as a drug candidate for any indication.
RegeneRx’s choice
RegeneRx’s clinical development used full-length Tβ4 throughout, a deliberate choice reflecting the broader functional profile of the intact protein.
Why this choice matters
If the TB-500 fragment had the same therapeutic potential as full-length Tβ4, pharmaceutical companies would have strong incentives to develop it — fragments are smaller, easier to manufacture, more stable, and cheaper to produce.
But they didn’t. Not a single pharmaceutical company pursued the TB-500 fragment. This at least suggests that the extra functional regions of the full protein have irreplaceable therapeutic value.
What this means for users
When the pharmaceutical industry — the player with the most resources and the deepest understanding of these molecules — consistently chooses the full-length protein over the fragment, that choice itself is an important signal.
Conclusion
Pharma’s choice was not accidental. Understanding why they chose full-length Tβ4 helps assess TB-500’s actual positioning more accurately.